Business Description
PharmaEngine Inc
NAICS : 325412
SIC : 2834
ISIN : TW0004162003
Description
PharmaEngine Inc is a biopharmaceutical company engaged in the development of new drugs and therapeutic drugs for cancer. It is a specialty pharma company that adopts the no research, development-only model and the networked pharma model for new drug development. Its projects pipeline are: ONIVYDE was approved by the U.S. FDA, Taiwan FDA, and EMA for patients with gemcitabine-treated metastatic pancreatic cancer; and PEP07. It generates the revenue from Sales of goods.
Financial Strength
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 287.53 | |||||
Equity-to-Asset | 0.97 | |||||
Debt-to-EBITDA | 0.04 | |||||
Interest Coverage | 951.17 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 71.96 | |||||
Beneish M-Score | -2.45 | |||||
WACC vs ROIC |
Growth Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -9.6 | |||||
3-Year EBITDA Growth Rate | -22.8 | |||||
3-Year EPS without NRI Growth Rate | -22.7 | |||||
3-Year FCF Growth Rate | 59.5 | |||||
3-Year Book Growth Rate | -0.8 |
Momentum Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 50.52 | |||||
9-Day RSI | 51.47 | |||||
14-Day RSI | 52.09 | |||||
6-1 Month Momentum % | -7.02 | |||||
12-1 Month Momentum % | 8.05 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 36.85 | |||||
Quick Ratio | 36.54 | |||||
Cash Ratio | 33.88 | |||||
Days Inventory | 215.79 | |||||
Days Sales Outstanding | 36.7 | |||||
Days Payable | 251.66 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 2.06 | |||||
Dividend Payout Ratio | 1.05 | |||||
3-Year Dividend Growth Rate | 58.7 | |||||
Forward Dividend Yield % | 2.06 | |||||
5-Year Yield-on-Cost % | 3.93 | |||||
3-Year Average Share Buyback Ratio | 0.4 | |||||
Shareholder Yield % | 2.06 |
Profitability Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 93.96 | |||||
Operating Margin % | 34.5 | |||||
Net Margin % | 36 | |||||
FCF Margin % | 32.75 | |||||
ROE % | 7.11 | |||||
ROA % | 6.83 | |||||
ROIC % | 101.61 | |||||
ROC (Joel Greenblatt) % | 305.89 | |||||
ROCE % | 8.73 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 50.79 | |||||
PE Ratio without NRI | 50.79 | |||||
Shiller PE Ratio | 33.1 | |||||
Price-to-Owner-Earnings | 49.87 | |||||
PEG Ratio | 1.64 | |||||
PS Ratio | 18.3 | |||||
PB Ratio | 3.53 | |||||
Price-to-Tangible-Book | 3.53 | |||||
Price-to-Free-Cash-Flow | 55.81 | |||||
Price-to-Operating-Cash-Flow | 55.63 | |||||
EV-to-EBIT | 30.25 | |||||
EV-to-EBITDA | 29.46 | |||||
EV-to-Revenue | 13.41 | |||||
EV-to-FCF | 40.12 | |||||
Price-to-Projected-FCF | 1.62 | |||||
Price-to-Median-PS-Value | 0.73 | |||||
Price-to-Peter-Lynch-Fair-Value | 2.03 | |||||
Price-to-Graham-Number | 2.82 | |||||
Price-to-Net-Current-Asset-Value | 3.56 | |||||
Price-to-Net-Cash | 3.88 | |||||
Earnings Yield (Greenblatt) % | 3.3 | |||||
FCF Yield % | 1.8 | |||||
Forward Rate of Return (Yacktman) % | 22.14 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
PharmaEngine Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil NT$) | 763.807 | ||
EPS (TTM) (NT$) | 1.91 | ||
Beta | 0.55 | ||
Volatility % | 39.41 | ||
14-Day RSI | 52.09 | ||
14-Day ATR (NT$) | 2.643503 | ||
20-Day SMA (NT$) | 96.445 | ||
12-1 Month Momentum % | 8.05 | ||
52-Week Range (NT$) | 79.8 - 122.5 | ||
Shares Outstanding (Mil) | 143.68 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 5 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
PharmaEngine Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
PharmaEngine Inc Stock Events
Event | Date | Price(NT$) | ||
---|---|---|---|---|
No Event Data |
PharmaEngine Inc Frequently Asked Questions
What is PharmaEngine Inc(ROCO:4162)'s stock price today?
The current price of ROCO:4162 is NT$97.00. The 52 week high of ROCO:4162 is NT$122.50 and 52 week low is NT$79.80.
When is next earnings date of PharmaEngine Inc(ROCO:4162)?
The next earnings date of PharmaEngine Inc(ROCO:4162) is .
Does PharmaEngine Inc(ROCO:4162) pay dividends? If so, how much?
The Dividend Yield % of PharmaEngine Inc(ROCO:4162) is 2.06% (As of Today), Highest Dividend Payout Ratio of PharmaEngine Inc(ROCO:4162) was 3.45. The lowest was 0.12. And the median was 0.86. The Forward Dividend Yield % of PharmaEngine Inc(ROCO:4162) is 2.06%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |